Jay L Koyner1, Lakhmir S Chawla2, Azra Bihorac3, Kyle J Gunnerson4, Rebecca Schroeder5, Sevag Demirjian6, Luke Hodgson7, Jennifer A Frey8, Scott T Wilber9, J Patrick Kampf10, Thomas Kwan10, Paul McPherson10, John A Kellum11. 1. Section of Nephrology, Department of Medicine, University of Chicago, Chicago, Illinois. 2. Veterans Affairs Medical Center, San Diego, California. 3. Division of Nephrology, Hypertension, and Renal Transplantation, University of Florida, Gainesville, Florida. 4. Department of Emergency Medicine, University of Michigan Health, Michigan Center for Integrative Research in Critical Care (MCIRCC), Ann Arbor, Michigan. 5. Department of Anesthesiology, Duke University School of Medicine, VA Health Care System, Durham, North Carolina. 6. Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, Ohio. 7. Worthing Hospital, University Hospitals Sussex, Worthing, United Kingdom. 8. Department of Emergency Medicine, Ohio State University, Columbus, Ohio. 9. Mount Carmel East Hospital, Mount Carmel Health System, Columbus, Ohio. 10. Astute Medical, Inc., San Diego, California. 11. Department of Critical Care Medicine, Center for Critical Care Nephrology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Abstract
Background: Clinical use of biomarkers requires the development of standardized assays and establishment of cutoffs. Urinary C-C motif chemokine ligand 14 (CCL14) has been validated to predict persistent severe AKI in critically ill patients with established AKI. We now report on the performance of standardized cutoffs using a clinical assay. Methods: A second aim of the multicenter RUBY Study was to establish two cutoffs for the prediction of persistent severe AKI (defined as KDIGO stage 3 AKI for at least 72 consecutive hours). Patients who received renal replacement therapy (RRT) or died before achieving 72 hours in stage 3 AKI were also considered to have reached the end point. Results: A cutoff value for urinary CCL14 of 1.3 ng/ml was determined to achieve high sensitivity (91%; 95% CI, 84% to 96%), and 13 ng/ml achieved high specificity (93%; 95% CI, 89% to 96%). The cutoff of 1.3 ng/ml identifies the majority (91%) of patients who developed persistent severe AKI with a negative predictive value of 92%. The cutoff at 13 ng/ml had a positive predictive value of 72% (with a negative predictive value of 75%). In multivariable adjusted analyses, a CCL14 concentration between 1.3 and 13 ng/ml had an adjusted odds ratio (aOR) of 3.82 (95% CI, 1.73 to 9.12; P=0.001) for the development of persistent severe AKI compared with those with a CCL14 ≤1.3 ng/ml, whereas a CCL14 >13 ng/ml had an aOR of 10.4 (95% CI, 3.89 to 29.9; P<0.001). Conclusions: Using a clinical assay, these standardized cutoffs (1.3 and 13 ng/ml) allow for the identification of patients at high risk for the development of persistent severe AKI. These results have immediate utility in helping to guide AKI patient care and may facilitate future clinical trials.Clinical Trial registry name and registration number: Identification and Validation of Biomarkers of Acute Kidney Injury Recovery, NCT01868724.
Background: Clinical use of biomarkers requires the development of standardized assays and establishment of cutoffs. Urinary C-C motif chemokine ligand 14 (CCL14) has been validated to predict persistent severe AKI in critically ill patients with established AKI. We now report on the performance of standardized cutoffs using a clinical assay. Methods: A second aim of the multicenter RUBY Study was to establish two cutoffs for the prediction of persistent severe AKI (defined as KDIGO stage 3 AKI for at least 72 consecutive hours). Patients who received renal replacement therapy (RRT) or died before achieving 72 hours in stage 3 AKI were also considered to have reached the end point. Results: A cutoff value for urinary CCL14 of 1.3 ng/ml was determined to achieve high sensitivity (91%; 95% CI, 84% to 96%), and 13 ng/ml achieved high specificity (93%; 95% CI, 89% to 96%). The cutoff of 1.3 ng/ml identifies the majority (91%) of patients who developed persistent severe AKI with a negative predictive value of 92%. The cutoff at 13 ng/ml had a positive predictive value of 72% (with a negative predictive value of 75%). In multivariable adjusted analyses, a CCL14 concentration between 1.3 and 13 ng/ml had an adjusted odds ratio (aOR) of 3.82 (95% CI, 1.73 to 9.12; P=0.001) for the development of persistent severe AKI compared with those with a CCL14 ≤1.3 ng/ml, whereas a CCL14 >13 ng/ml had an aOR of 10.4 (95% CI, 3.89 to 29.9; P<0.001). Conclusions: Using a clinical assay, these standardized cutoffs (1.3 and 13 ng/ml) allow for the identification of patients at high risk for the development of persistent severe AKI. These results have immediate utility in helping to guide AKI patient care and may facilitate future clinical trials.Clinical Trial registry name and registration number: Identification and Validation of Biomarkers of Acute Kidney Injury Recovery, NCT01868724.
Authors: Ron Wald; Neill K J Adhikari; Orla M Smith; Matthew A Weir; Karen Pope; Ashley Cohen; Kevin Thorpe; Lauralyn McIntyre; Francois Lamontagne; Mark Soth; Margaret Herridge; Stephen Lapinsky; Edward Clark; Amit X Garg; Swapnil Hiremath; David Klein; C David Mazer; Robert M A Richardson; M Elizabeth Wilcox; Jan O Friedrich; Karen E A Burns; Sean M Bagshaw Journal: Kidney Int Date: 2015-07-08 Impact factor: 10.612
Authors: Christina Massoth; Mira Küllmar; Dominic Enders; John A Kellum; Lui G Forni; Melanie Meersch; Alexander Zarbock Journal: J Thorac Cardiovasc Surg Date: 2021-03-10 Impact factor: 5.209
Authors: Nandkishor S Chindarkar; Lakhmir S Chawla; Joely A Straseski; Saeed A Jortani; Denise Uettwiller-Geiger; Robert R Orr; John A Kellum; Robert L Fitzgerald Journal: Clin Chim Acta Date: 2015-11-10 Impact factor: 3.786
Authors: Tezcan Ozrazgat-Baslanti; Tyler J Loftus; Rajesh Mohandas; Quran Wu; Scott Brakenridge; Babette Brumback; Philip A Efron; Stephen Anton; Frederick A Moore; Lyle L Moldawer; Mark S Segal; Azra Bihorac Journal: Ann Surg Date: 2020-11-13 Impact factor: 13.787
Authors: Matthew M Churpek; Kyle A Carey; Dana P Edelson; Tripti Singh; Brad C Astor; Emily R Gilbert; Christopher Winslow; Nirav Shah; Majid Afshar; Jay L Koyner Journal: JAMA Netw Open Date: 2020-08-03